Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J. Fox Foundation for Parkinson’s ...

Spanish drugmaker Grifols reported on Wednesday a net profit ... have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near ...

In this article, we are going to take a look at where Grifols, S.A. (NASDAQ:GRFS) stands against the other pharma stocks. The Rising Demand for Weight-Loss Medications and GLP-1 Developments ...

The drug has been available to NHS patients in Scotland since early 2021. Grifols – a Barcelona-based specialist in plasma-based therapies – said today that Tavlesse is the first and only SYK ...

A state-of-the-art manufacturing facility, with robotic arms and conveyor belts for drug production. Grifols, S.A. (NASDAQ:GRFS) is a Spanish global healthcare company specializing in plasma ...

Grifols has shared positive results from its clinical trial evaluating the efficacy and safety of intravenous immunoglobulin to treat patients with PPS.

Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety of intravenous immunoglobulin (IVIG) to treat post-polio syndrome (PPS). The study showed ...

Grifols (GRFS) issued a statement to address certain information published in a media outlet on March 8, specifically a front-page article titled “The CNMV reveals to the judge ‘continuous ...

Biopharmaceutical companies also use it to manufacture life-saving drugs. Unlike those going toward ... by one of three companies: CSL Plasma, Grifols, and BioLife. Even before the pandemic ...